Sign in to view content

Platform for Screening Compounds for Treatment of AMD Using iPSC-derived human RPE: Examples Using Elamipretide and SBT-272

Lucian V. Del Priore, MD, PhD

Video
Published 2022

Related

One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024

Category: AMD-Non-Neovascular

See more